October 3, 2026 
3 min read
Back to Blog
William "Wes" Alden, MD, PhD | Clinical Education Series
Insulin Resistance, Metabolic Syndrome, and the Brain
By William “Wes” Alden, MD, PhD
Metabolic health in mid-life shapes the brain’s future. Insulin resistance, extra visceral fat, abnormal lipids, high blood pressure, and low-grade inflammation travel together and raise the risk of both vascular cognitive impairment and Alzheimer-type changes. The encouraging part is that most of these factors can be improved.
How metabolism reaches the brain
Brain tissue responds to insulin. When resistance develops, glucose use becomes less efficient and inflammatory signals rise. Large observational studies link the metabolic syndrome to higher rates of later cognitive decline.
GLP-1 medicines and related agents
Semaglutide, tirzepatide, and similar drugs are approved for type 2 diabetes and, in specific versions, for chronic weight management and cardiovascular risk reduction. They improve glucose control, reduce weight, and in outcome trials lower major cardiac events. They are not approved as treatments for dementia, but better metabolic control itself is a reasonable part of protecting the brain.
Lifestyle still leads
Food pattern, combined aerobic and strength exercise, sleep, and stress management come first. Losing visceral fat improves insulin sensitivity and lowers inflammatory tone. These steps carry broader evidence and lower risk than most drugs or supplements.
Lipids in the same picture
Triglyceride-rich particles and low HDL often accompany insulin resistance. Prescription omega-3 products have clear roles when triglycerides are very high or when a patient fits the profile studied in REDUCE-IT. Overall lipid care should follow ordinary cardiovascular guidelines; the brain benefits when vessels stay healthier.
Putting it to work
Treating insulin resistance and the metabolic syndrome is one of the most practical ways an internist can support long-term brain health. The tools are already familiar: lifestyle change, metformin when appropriate, GLP-1 or dual agonists for the right patients, blood-pressure control, and lipid management. Naming these steps as cognitive protection helps patients stay engaged without promising unproven therapies.
William “Wes” Alden, MD, PhD, is a physician-scientist and internist. His career has included academic medicine, federal clinical research, community practice, and medical philanthropy. He works in the Greater New Orleans area, including Metairie, New Orleans, and the Northshore communities of Mandeville and Covington. His interests include metabolic health, integrative approaches, neurodegenerative conditions, and practical whole-person care. He emphasizes honest evidence and clear communication with patients and families.
This article is for general education and reflects Dr. Alden’s professional perspective. It is not medical advice and does not create a doctor-patient relationship. Results vary from person to person. Many peptides, NAD products, and specialty lipids mentioned here are not FDA-approved for anti-aging, cognitive enhancement, or most of the wellness uses sometimes promoted. Material labeled for research use only should never be given to people. Please consult a qualified clinician about your own situation before starting any evaluation or treatment.
